American Heart Journal
Volume 157, Issue 1 , Pages 9-21 , January 2009

Cardiac sarcoidosis

  • Jessica S. Kim, BS

      Affiliations

    • New York University School of Medicine, New York, NY
    • Corresponding Author InformationReprint requests: Jessica S. Kim, BS, New York University School of Medicine, 550 First Avenue, SLH New York, NY 10016.
    • ,
  • Marc A. Judson, MD

      Affiliations

    • Medical University of South Carolina, Charleston, SC
    • ,
  • Robert Donnino, MD

      Affiliations

    • New York University School of Medicine, New York, NY
    • ,
  • Michael Gold, MD, PhD

      Affiliations

    • Medical University of South Carolina, Charleston, SC
    • ,
  • Leslie T. Cooper Jr, MD

      Affiliations

    • Mayo Clinic, Rochester, MN
    • ,
  • Eric N. Prystowsky, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • Stephen Prystowsky, MD

      Affiliations

    • New York University School of Medicine, New York, NY

Received 27 June 2008 ,Accepted 11 September 2008.

References 

  1. Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients and review of 78 previously described necropsy patients. Am J Med. 1977;63:86–108
  2. Hillerdal O, Niou E, Osterman K. Sarcoidosis. Epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130:29–32
  3. Rybicki BA, Major M, Popovich J, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–241
  4. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev. 1983;5:124–156
  5. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111–1118
  6. Smith G, Brownell I, Sanchez M, et al. Advances in the genetics of sarcoid. Clin Genet. 2008;73:1–12
  7. Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: new pathogenic insights. Sarcoidosis Vasc Diff Lung Dis. 2002;19:83–95
  8. Grutters JC, Sato H, Pantelides P, et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am Rev Respir Crit Care Med. 2002;165:1119–1124
  9. Takada T, Suzuki E, Morohash K, et al. Association of single nucleotide polymorphisms in the IL-18 gene with sarcoidosis in a Japanese population. J Rheumatol. 2002;29:1671–1673
  10. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1⁎1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73:720–735
  11. Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37:357–364
  12. Rybicki BA, Walewski JL, Maliarik MJ, et al. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet. 2005;77:491–499
  13. Cooper LT. Giant cell and granulomatous myocarditis. Heart Fail Clin. 2005;1:431–437
  14. Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11:26–31
  15. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167–172
  16. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–1211
  17. Cooper LT. Cardiac sarcoidosis. In:  Cooper LT editors. Myocarditis: From Bench to Bedside. Totowa (NJ): Humana Press; 2002;p. 421–436
  18. Iwai K, Tachibana T, Takemura T. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43:372–376
  19. Desai MY, Fallert MA. Rapidly progressing congestive heart failure due to cardiac sarcoidosis involving papillary muscles: a case report and brief review of the literature. Cardiol Rev. 2003;11:163–168
  20. Cross B, Nicolarsen J, Bullock J, et al. Cardiac sarcoidosis presenting as mitral regurgitation. J Am Soc Echocardiogr. 2007;20:9069.e6–9069.e13
  21. Halushka MK, Yuh DD, Russell SD. Right ventricle-dominant cardiac sarcoidosis with sparing of the left ventricle. J Heart Lung Transplant. 2006;25:479–482
  22. Goyal SB, Aragam JR. Cardiac sarcoidosis with primary involvement of the tricuspid valve. Cardiol Rev. 2006;14:e12–e13
  23. Butany J, Bahl NE, Morales K, et al. The intricacies of cardiac sarcoidosis: a case report involving the coronary arteries and a review of the literature. Cardiovasc Pathol. 2006;15:222–227
  24. Lam CSP, Tolep KA, Metke MP, et al. Coronary sarcoidosis presenting as acute coronary syndrome. Clin Cardiol. 2008;[in press]
  25. Abrishami B, O'Connel C, Sharma O. Cardiac sarcoidosis with presentation of large left atrial mass. Curr Opin Pulm Med. 2004;10:397–400
  26. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83:315–334
  27. Okura Y, Dec GW, Hare JM, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41:322–328
  28. Nelson JE, Kirschner PA, Teirstein AS. Sarcoidosis presenting as heart disease. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13:178–182
  29. Fleming HA, Bailey SM. Sarcoid heart disease. J R Coll Physicians London 1981;15:245–246, 249–523.
  30. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann New York Acad Sci. 1976;278:455–469
  31. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest. 2005;128:30–35
  32. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010
  33. Fleming HA. Sarcoid heart disease. Br Heart J. 1974;36:54–68
  34. Gasparovic H, Bueno R, Rybicki FJ, et al. Sarcoidosis of the aortic root. J Thorac Cardiovasc Surg. 2004;128:761–762
  35. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129:1246–1252
  36. Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med. 2007;13:434–438
  37. Konno T, Shimizu M, Ino H, et al. A rare type of alternating bundle branch block in a patient with cardiac sarcoidosis—a case report. Angiology. 2005;56:115–117
  38. Ramachandran V, Stevens MP, Amin M, et al. Bi-fascicular block on EKG as the initial presenting sign of cardiac sarcoidosis. Int J Cardiol. 2007;118:e1–e2
  39. Ahmad K, Kim YH, Spitzer AR, et al. Total nodal radiation in progressive sarcoidosis. Case report. Am J Clin Oncol. 1992;15:311–313
  40. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18:937–943
  41. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–282
  42. Kinney E, Murthy R, Ascunce G, et al. Pericardial effusions in sarcoidosis. Chest. 1979;76:476–478
  43. Zelcer AA, LeJemtel TH, Jones J, et al. Pericardial tamponade in sarcoidosis. Can J Cardiol. 1987;3:12–13
  44. Garrett J, O'Neill H, Blake S. Sarcoidosis of the heart. Am Heart J. 1984;107:394
  45. Hiraga H, Yuwai K, Hiroe M, et al. In: Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases from the Japanese Ministry of Health and Welfare. Tokyo: Japanese Ministry of Health and Welfare; 1993;p. 23–24
  46. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86
  47. Judson MA. A proposed solution to the clinical assessment of sarcoidosis: the sarcoidosis three-dimensional assessment instrument (STAI). Med Hypotheses. 2007;68:1080–1087
  48. Ratner SJ, Fenoglio JJ, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest. 1986;90:528–533
  49. Weinberg M, Fell EH, Lynfield J. Diagnostic biopsy of the pericardium and myocardium. AMA Arch Surg. 1958;76:825–829
  50. Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J. 2005;150:459–463
  51. Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol. 2005;185:110–115
  52. Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138:299–302
  53. Pandya C, Brunken RC, Tchou P, et al. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J. 2007;29:418–422
  54. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914–1931
  55. Sekiguchi M, Yazaki Y, Isobe M, et al. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther. 1996;10:495–510
  56. Numao Y, Sekiguchi M, Hirosawa K, et al. Evaluation of cardiac involvement through electrocardiogram in patients with sarcoidosis. Kokyu To Junkan. 1981;29:421–428
  57. Judson MA. Cardiac sarcoidosis: there is no instant replay. Chest. 2005;128:3–6
  58. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426–1435
  59. Kinney EL, Jackson GL, Reeves WC, et al. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. Am J Med. 1980;68:497–503
  60. Lewin RF, Mor R, Spitzer S, et al. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J. 1985;110:116–122
  61. Burstow DJ, Tajik J, Baily KR, et al. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol. 1989;63:478–482
  62. Gibbons WJ, Levy RD, Nava S, et al. Subclinical cardiac dysfunction in sarcoidosis. Chest. 1991;100:44–50
  63. Angomachelelis N, Hourzamanis A, Vamvalis C, et al. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J. 1992;68:S52–S56
  64. Fahy GJ, Warwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest. 1996;109:62–66
  65. Hyodo E, Hozumi T, Takemoto Y, et al. Early detection of cardiac involvement in patients with sarcoidosis by a non-invasive method with ultrasonic tissue characterisation. Heart. 2004;90:1275–1280
  66. Hourigan LA, Burstow DJ, Pohlner P, et al. Transesophageal echocardiographic abnormalities in a case of cardiac sarcoidosis. J Am Soc Echocardiogr. 2001;14:399–402
  67. Yamano T, Nakatani S. Cardiac sarcoidosis: what can we know from echocardiography?. J Echocardiogr. 2007;5:1–10
  68. Bulkley BH, Rouleau JB, Whitaker JQ, et al. The use of 201thallium for myocardial perfusion imaging in sarcoid heart disease. Chest. 1977;72:27–32
  69. Tellier P, Paycha F, Antony I, et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med. 1988;85:189–193
  70. Le Guludec D, Menad F, Faraggi M, et al. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest. 1994;106:1675–1682
  71. Tellier P, Valeyre A, Nitenberg A, et al. Cardiac sarcoidosis: reversion of myocardial perfusion abnormalities by dipyridamole. Eur J Nucl Med. 1985;11:201–204
  72. Haywood LJ, Sharma OP, Siegel ME, et al. Detection of myocardial sarcoidosis by thallium 201 imaging. J Natl Med Assoc. 1982;74:959–964
  73. Fields G, Ossorio M, Roy T, et al. Thallium 201 scintigraphy in the diagnosis the management of myocardial sarcoidosis. South Med J. 1990;83:339–342
  74. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med. 2003;44:1030–1036
  75. Kaminaga T, Takeshita T, Yamauchi T, et al. The role of iodine-123–labeled 15-(p-iodophenyl)-3R, S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis. Int J Cardiol. 2004;94:99–103
  76. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–1998
  77. Kinney EL, Caldwell JW. Do thallium myocardial perfusion scan abnormalities predict survival in sarcoid patients without cardiac symptoms?. Angiology. 1990;41:573–576
  78. Kinney EL, Jackson GL, Reeves WC, et al. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients. Am J Med. 1980;68:497–503
  79. Okayama K, Kurata C, Tawarahara K, et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107:330–334
  80. Kiuchi S, Teraoka K, Koizumi K, et al. Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging. 2007;23:237–241
  81. Nakazawa A, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest. 2004;126:1372–1376
  82. Brudin LH, Valind S, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21:297–305
  83. Lewis P, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–1649
  84. Yokoyama I, Momomura S, Ohtake T, et al. Role of positron emission tomography using fluorine-18 fluoro-2-deoxyglucose in predicting improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy. EurJ Nucl Med. 1998;25:736–743
  85. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–1543
  86. Smedema JP, Reenaers V, Geukens R. Cardiac sarcoidosis in a 60-year-old woman. Heart. 2006;92:688
  87. Takeda N, Yokoyama I, Hiroi Y, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation. 2002;105:1144–1145
  88. Tadamura E, Yamamuro M, Kubo S, et al. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation. 2006;113:e771–e773
  89. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–941
  90. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;35:19–28
  91. Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21–26
  92. Knapp WH, Bentrup A, Ohlmeier H. Indium-111-labelled antimyosin antibody imaging in a patient with cardiac sarcoidosis. Eur J Nucl Med. 1993;20:80–82
  93. Matsuki M, Matsuo M. MR findings of myocardial sarcoidosis. Clin Radiol. 2000;55:323–325
  94. Inoue S, Shimada T, Murakami Y. Clinical significance of gadolinium-DTPA-enhanced MRI for detection of myocardial lesions in a patient with sarcoidosis. Clin Radiol. 1999;54:70–72
  95. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med. 2001;110:520–527
  96. Vignaux O, Dhote R, Dudoc D, Blanche P, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002;26:762–767
  97. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol. 2005;184:249–254
  98. Smedema JP, Snoep G, Van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–1690
  99. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992–2002
  100. Vignaux O, Dhôte R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis. A 1-year follow-up study. Chest. 2002;122:1895–1901
  101. Doherty MJ, Kumar K, Nicholson AA, et al. Cardiac sarcoidosis: the value of magnetic resonance imagine in diagnosis and assessment of response to treatment. Respir Med. 1998;92:697–699
  102. Smedema J, Truter R, de Klerk P, et al. Cardiac sarcoidosis evaluated with gadolinium-enhanced magnetic resonance and contrast-enhanced 64-slice computed tomography. Int J Cardiol. 2006;112:261–263
  103. Kanao S, Tadamura E, Yamamuro M, et al. Demonstration of cardiac involvement of sarcoidosis by contrast-enhanced multislice computed tomography and delayed-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2005;29:745–748
  104. Doughan A, Williams B. Cardiac sarcoidosis. Heart. 2006;92:282–288
  105. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  106. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  107. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation. 2008;117:2820–2840
  108. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J. 2006;28:627–636
  109. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143–146
  110. Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004;97:173–182
  111. Kato Y, Morimoto S, Uemura A, et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133–137
  112. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–2259
  113. Stanton C, Mookadam F, Cha S, et al. Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy. Int J Cardiol. 2008;128:38–41
  114. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802
  115. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533–548
  116. Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:133–137
  117. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192–197
  118. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117–1122
  119. Demeter SL. Myocardial sarcoidosis unresponsive to steroids: treatment with cyclophosphamide. Chest. 1988;94:202–203
  120. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227–232
  121. Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol. 2007;26:2001–2003
  122. Oni A, Hershberger R, Norman D, et al. Recurrence of sarcoidosis in a cardiac allograft control with augmented corticosteroids. J Heart Lung Transplant. 1992;11:367–369
  123. Yager J, Hernandez A, Steenbergen C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant. 2005;24:1988–1990
  124. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant. 2007;26:714–717
  125. Burke WMJ, Keogh A, Maloney PJ, et al. Transmission of sarcoidosis via cardiac transplantation. Lancet. 1990;336:1579
  126. Daimon M, Sasaki T, Woo E, et al. Successful surgical treatment for dilated cardiomyopathy with cardiac sarcoidosis. Ann Thorac Surg. 2007;84:e12–e13
  127. Jain A, Starek PJ, Delany DL. Ventricular tachycardia and ventricular aneurysm due to unrecognized sarcoidosis. Clin Cardiol. 1990;13:738–740
  128. Lull RJ, Dunn BE, Gregoratos G, et al. Ventricular aneurysm due to cardiac sarcoidosis with surgical cure of refractory ventricular tachycardia. Am J Cardiol. 1972;30:282–287

PII: S0002-8703(08)00799-0

doi: 10.1016/j.ahj.2008.09.009

American Heart Journal
Volume 157, Issue 1 , Pages 9-21 , January 2009

Article Tools

* Image Usage & Resolution